Amgen, Inc. (AMGN) Shares Bought by Family Legacy Inc.

Family Legacy Inc. lifted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 70.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,060 shares of the medical research company’s stock after acquiring an additional 4,560 shares during the period. Amgen comprises approximately 1.7% of Family Legacy Inc.’s holdings, making the stock its 18th largest holding. Family Legacy Inc.’s holdings in Amgen were worth $1,923,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of AMGN. Baker Ellis Asset Management LLC bought a new position in Amgen during the 3rd quarter worth $108,000. Phocas Financial Corp. bought a new position in Amgen during the 2nd quarter worth $110,000. Jackson Grant Investment Advisers Inc. grew its stake in Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares during the last quarter. Omnia Family Wealth LLC grew its stake in Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after buying an additional 147 shares during the last quarter. Finally, Horan Capital Advisors LLC. bought a new position in Amgen during the 3rd quarter worth $150,000. 79.53% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders sold 4,575 shares of company stock valued at $838,064. Insiders own 0.19% of the company’s stock.

AMGN has been the subject of a number of recent research reports. Argus upgraded Amgen from a “hold” rating to a “buy” rating and upped their price objective for the stock from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Citigroup downgraded Amgen to a “neutral” rating in a research note on Monday, December 18th. JPMorgan Chase restated a “hold” rating and set a $191.00 price objective on shares of Amgen in a research note on Sunday, February 4th. Goldman Sachs downgraded Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Mizuho set a $192.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Friday, December 22nd. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $190.57.

Shares of Amgen stock opened at $168.14 on Friday. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $125,031.95, a PE ratio of 13.37, a PEG ratio of 2.13 and a beta of 1.36. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.89 EPS. equities analysts anticipate that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.

Amgen announced that its Board of Directors has approved a stock repurchase plan on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 annualized dividend and a dividend yield of 3.14%. Amgen’s dividend payout ratio (DPR) is 41.97%.

COPYRIGHT VIOLATION WARNING: “Amgen, Inc. (AMGN) Shares Bought by Family Legacy Inc.” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/family-legacy-inc-acquires-4560-shares-of-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply